Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Fusion”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Not applicableNot Yet RecruitingNCT06466031
What this trial is testing

Application of MET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme

Who this might be right for
Glioblastoma Multiforme
Copernicus Memorial Hospital 189
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Not applicableNot Yet RecruitingNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT01639508
What this trial is testing

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Who this might be right for
Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 86
Testing effectiveness (Phase 2)Ended earlyNCT02587650
What this trial is testing

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Who this might be right for
ALK Fusion Protein ExpressionBRAF wt AlleleInvasive Skin Melanoma+12 more
University of California, San Francisco 1
Large-scale testing (Phase 3)Looking for participantsNCT06988475
What this trial is testing

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

Who this might be right for
Solid TumourHaematological MalignancyMalignant Neoplasm+8 more
Cancer Research UK 30
Early research (Phase 1)Active Not RecruitingNCT03333343
What this trial is testing

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Who this might be right for
EGFR-mutant Non-small Cell Lung Cancer
Novartis Pharmaceuticals 105
Early research (Phase 1)Study completedNCT02978261
What this trial is testing

Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas

Who this might be right for
Glioma
Beijing Pearl Biotechnology Limited Liability Company 18
Early research (Phase 1)Active Not RecruitingNCT03993873
What this trial is testing

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorsMET Gene Alterations
Turning Point Therapeutics, Inc. 95